The Histone Deacetylase Inhibitor NVP-LAQ824 Inhibits Angiogenesis and Has a Greater Antitumor Effect in Combination with the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor PTK787/ZK222584

The Hallmarks of Cancer

2000 • 27,569 citations

Patterns and Emerging Mechanisms of the Angiogenic Switch during Tumorigenesis

1996 • 6,878 citations

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1984 • 6,841 citations

The fundamental role of epigenetic events in cancer

2002 • 5,532 citations

Hypoxia — a key regulatory factor in tumour growth

2002 • 4,942 citations

Genetic instabilities in human cancers

1998 • 4,165 citations

Vascular-specific growth factors and blood vessel formation

2000 • 3,667 citations

Clinical translation of angiogenesis inhibitors

2002 • 1,518 citations

Histone-deacetylase inhibitors: novel drugs for the treatment of cancer

2002 • 1,497 citations

VEGF and the quest for tumour angiogenesis factors

2002 • 1,467 citations

Angiopoietin-1 protects the adult vasculature against plasma leakage

2000 • 1,271 citations

Validating survivin as a cancer therapeutic target

2003 • 1,206 citations

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

2000 • 1,159 citations

Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells

2000 • 1,158 citations

Acetylation: a regulatory modification to rival phosphorylation?

2000 • 1,136 citations

PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.

2000 • 848 citations

What's Up and Down with Histone Deacetylation and Transcription?

1997 • 831 citations

A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.

1992 • 807 citations

Clinical Application of Antiangiogenic Therapy: Microvessel Density, What It Does and Doesn't Tell Us

2002 • 794 citations

New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF

1999 • 751 citations

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

2001 • 729 citations

Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody

1996 • 718 citations

Regulation and Destabilization of HIF-1α by ARD1-Mediated Acetylation

2002 • 693 citations

Combined effects of angiostatin and ionizing radiation in antitumour therapy

1998 • 679 citations

Hsp90 inhibitors as novel cancer chemotherapeutic agents

2002 • 673 citations

Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for the Pharmacological Response of PTK787/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies

2003 • 651 citations

Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1.

2001 • 550 citations

A role for survivin in chemoresistance of endothelial cells mediated by VEGF

2002 • 438 citations

Regulation of Transcription Factor YY1 by Acetylation and Deacetylation

2001 • 405 citations

Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling

2002 • 389 citations

Tyrosine kinase inhibitors: From rational design to clinical trials

2001 • 325 citations

Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model.

2000 • 314 citations

Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.

2003 • 282 citations

Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis

2000 • 267 citations

HIF-1: using two hands to flip the angiogenic switch.

2000 • 235 citations

Antiangiogenic therapy and tumor progression

2004 • 233 citations

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

2003 • 220 citations

Inhibitors of Histone Deacetylation Downregulate the Expression of Endothelial Nitric Oxide Synthase and Compromise Endothelial Cell Function in Vasorelaxation and Angiogenesis

2002 • 198 citations

Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1α activity

2003 • 165 citations

Selective Growth Inhibition of Tumor Cells by a Novel Histone Deacetylase Inhibitor, NVP-LAQ824

2004 • 135 citations

Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results.

2001 • 132 citations

Combination of phenylbutyrate and 13-cis retinoic acid inhibits prostate tumor growth and angiogenesis.

2001 • 113 citations

Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584

2003 • 99 citations

Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells

2001 • 45 citations